SAFC will extend its focus on high potency production through a number of new investments.
Outsourcing-Pharma presents its round-up of the latest appointments within the pharmaceutical industry, with news from Sucampo, Tranzyme, and Next Pharma.
Lonza may build a stem cell production facility dedicated to manufacturing Mesoblast products after inking an alliance.
Peptide-based therapeutics specialists Unigene will focus on high valuation drug development and drug delivery opportunities after cutting loose its Site Directed Bone Growth (SDBG) patent portfolio.
in-PharmaTechnologist presents its round-up of the new appointments within the pharma biz, including news from Aduro, Catalent, and Eleven.
ProMetic Life Sciences is supplying an affinity adsorbent to a Chinese biopharm for use in scale-up of a biosimilar.
Catalent has struck up a deal with Toyobo Biologics to launch its cell line engineering technology on the Japanese market.
Alkermes has celebrated the launch of its new Irish drug delivery and formulation business by winning a new multimillion dollar manufacturing contract with a ‘top 10 pharma.’
GE Healthcare will expand its range of biomanufacturing technologies under a new oncology-focused investment project.
ShangPharma’s emerging discovery biology services unit has inked another antibody development partnership with a Chinese biopharm.
Biocon has begun work on the Malaysian biopharm plant that will serve its deal with Pfizer, and is now providing Lipitor ingredients.
Unilife has developed a wearable infusion device for self-administration of an emerging class of drugs that require large volume doses.
Contract manufacturer CMC Biologics has ramped-up bioreactor capacity to meet demand for biologic drugs for Phase III clinical trials and beyond.
Sartorius Stedium Biotech (SSB) and GE Healthcare Life Sciences say new cross licensing deal will aid development of their respective biomanufacturing tech offerings.
Privately-owned US biotech NanoSmart Pharmaceuticals says it has started work on a delivery platform for cancer drugs after moving into a new corporate HQ.